CTMX – cytomx therapeutics, inc. (US:NASDAQ)
Stock Stats
News
CytomX Therapeutics (CTMX) was downgraded by Weiss Ratings from "hold (c-)" to "sell (d)".
CytomX Therapeutics (CTMX) had its price target raised by Barclays PLC from $10.00 to $16.00. They now have an "overweight" rating on the stock.
CytomX Therapeutics (CTMX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level [Seeking Alpha]
CytomX Therapeutics (CTMX) had its price target raised by Guggenheim from $10.00 to $15.00. They now have a "buy" rating on the stock.
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: Chu Yu-Waye
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: McCarthy Sean A.
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: BELVIN MARCIA
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: Ogden Christopher
Form 8-K CytomX Therapeutics, For: Mar 17
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.